Clinical Trial Update: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) [Phase 2]

View source ↗

Summary

Phase 2 study in Japan evaluating the combination of ibrutinib with rituximab in Waldenström macroglobulinemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2022-12-01